Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Takahiro Tsuchikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3847-280X; OpenAlex author ID A5052504412. Sources: OpenAlex.

Their work

Papers
22 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 22

  1. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model. Co-author DOI 10.1016/j.biopha.2023.116052↗
  2. Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model. Co-author DOI 10.1038/s41417-024-00810-7↗
  3. Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells. First author DOI 10.3390/cancers15030601↗
  4. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  5. A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1016/j.pdpdt.2020.102157↗
  6. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. First author DOI 10.1097/mpa.0000000000001665↗
  7. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Co-author DOI 10.1158/1535-7163.mct-19-0491↗
  8. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? Co-author DOI 10.1007/s11605-018-3972-x↗
  9. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.1111/cas.14023↗
  10. [Ⅲ.Management of Biliary Drainage in Patients Undergoing Neo-Adjuvant Therapy for Biliary or Pancreatic Cancer]. Co-author PMID 31631131↗
  11. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. Co-author DOI 10.1002/jhbp.565↗
  12. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Co-author DOI 10.1038/s41417-018-0020-7↗
  13. Oncological emergency surgery for metachronous large and small bowel metastases after pancreaticoduodenectomy for pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-018-0506-4↗
  14. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal aden… Co-author DOI 10.1007/s00595-016-1420-7↗
  15. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Co-author DOI 10.18632/oncotarget.21939↗
  16. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1371/journal.pone.0152523↗
  17. Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v8.i11.786↗
  18. Concomitant major vessel resection in pancreatic adenocarcinoma. Co-author DOI 10.1080/00325481.2015.1032180↗
  19. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-14-2921↗
  20. Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Co-author DOI 10.18632/oncotarget.5729↗
  21. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. Co-author DOI 10.1111/cas.12119↗
  22. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. Co-author DOI 10.1007/s00534-011-0391-8↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Hirano · 22 shared papers, 2011–2024 · strength 1.84
  2. Toru Nakamura · 20 shared papers, 2013–2024 · strength 1.63
  3. Toshiaki Shichinohe · 18 shared papers, 2011–2024 · strength 1.36
  4. Yoshitsugu Nakanishi · 10 shared papers, 2017–2022 · strength 0.87
  5. Toshimichi Asano · 10 shared papers, 2017–2022 · strength 0.87
  6. Kazuho Inoko · 6 shared papers, 2015–2024 · strength 0.47
  7. Osamu Sato · 4 shared papers, 2017–2024 · strength 0.45
  8. Yuta Takeuchi · 2 shared papers, 2023–2024 · strength 0.33
  9. Shintaro Takeuchi · 5 shared papers, 2015–2018 · strength 0.28
  10. Toshihiro Kushibiki · 4 shared papers, 2015–2020 · strength 0.25
  11. Shota Kuwabara · 3 shared papers, 2017–2022 · strength 0.24
  12. Masato Ono · 3 shared papers, 2017–2022 · strength 0.24
  13. Hironobu Takano · 4 shared papers, 2015–2018 · strength 0.20
  14. Hiroki Niwa · 1 shared paper, 2024 · strength 0.18
  15. Yuma Hane · 2 shared papers, 2019–2020 · strength 0.17
  16. Shoki Sato · 3 shared papers, 2015–2018 · strength 0.16
  17. Yuko Omori · 1 shared paper, 2022 · strength 0.11
  18. Yusuke Mizukami · 1 shared paper, 2022 · strength 0.11
  19. Toru Furukawa · 1 shared paper, 2022 · strength 0.11
  20. Takahiro Saito · 1 shared paper, 2021 · strength 0.11
  21. Shinya Tanaka · 1 shared paper, 2020 · strength 0.08
  22. Kyoko Hida · 1 shared paper, 2020 · strength 0.08
  23. M Miyasaka · 1 shared paper, 2018 · strength 0.07
  24. Joe Matsumoto · 2 shared papers, 2011–2013 · strength 0.07
  25. Kentaro Kato · 2 shared papers, 2011–2013 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.